Weight-Loss drug shows promise in cutting heavy drinking
NCT ID NCT07292519
First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study tests whether a weekly injection of tirzepatide (a drug used for weight loss and diabetes) plus cognitive-behavioral therapy can help adults with alcohol use disorder and overweight or obesity reduce heavy drinking days. 46 participants will receive either the drug or a placebo for 8 weeks. The main goal is to see if the combination reduces the number of heavy drinking days compared to baseline.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMORBIDITIES AND COEXISTING CONDITIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Drug Health Services, Royal Prince Alfred Hospital
Sydney, New South Wales, 2050, Australia
Contact Phone: •••-•••-••••
Contact Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.